PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28860124-7	2017	Our study shows that treatment of NPC1I1061T fibroblasts with Vorinostat not only enhances pathways promoting the folding, stabilization and trafficking of NPC1 (I1061T) mutant to the LE/Ly, but alters the expression of lysosomal proteins, specifically the lysosomal acid lipase (LIPA) involved in the LIPA->NPC2->NPC1 based flow of cholesterol from the LE/Ly lumen to the LE/Ly membrane.	Vorinostat	62-72	NPC intracellular cholesterol transporter 1	Homo sapiens	34-38	
28860124-8	2017	We posit that the Vorinostat may modulate numerous pathways that operate in an integrated fashion through epigenetic and post-translational modifications reflecting acetylation/deacetylation balance to help manage the defective NPC1 fold, the function of the LE/Ly system and/or additional cholesterol metabolism/distribution pathways, that could globally contribute to improved mitigation of NPC1 disease in the clinic based on as yet uncharacterized principles of cellular metabolism dictating cholesterol homeostasis.	Vorinostat	18-28	NPC intracellular cholesterol transporter 1	Homo sapiens	228-232	
28860124-7	2017	Our study shows that treatment of NPC1I1061T fibroblasts with Vorinostat not only enhances pathways promoting the folding, stabilization and trafficking of NPC1 (I1061T) mutant to the LE/Ly, but alters the expression of lysosomal proteins, specifically the lysosomal acid lipase (LIPA) involved in the LIPA->NPC2->NPC1 based flow of cholesterol from the LE/Ly lumen to the LE/Ly membrane.	Vorinostat	62-72	NPC intracellular cholesterol transporter 1	Homo sapiens	156-160	
28193631-6	2017	Here, we show that several other human NPC1 mutant fibroblast cell lines can also be corrected by vorinostat or panobinostat and that treatment with vorinostat extends the lifetime of the NPC1I1061T protein.	Vorinostat	98-108	NPC intracellular cholesterol transporter 1	Homo sapiens	39-43	
28193631-5	2017	Treatment of patient-derived NPC1I1061T fibroblasts with histone deacetylase inhibitors (HDACis) vorinostat or panobinostat increases expression of the mutant NPC1 protein and leads to correction of the cholesterol storage.	Vorinostat	97-107	NPC intracellular cholesterol transporter 1	Homo sapiens	29-33	
28193631-6	2017	Here, we show that several other human NPC1 mutant fibroblast cell lines can also be corrected by vorinostat or panobinostat and that treatment with vorinostat extends the lifetime of the NPC1I1061T protein.	Vorinostat	149-159	NPC intracellular cholesterol transporter 1	Homo sapiens	39-43	
28031458-2	2017	Vorinostat, an FDA-approved inhibitor of histone deacetylases, ameliorates lysosomal lipid accumulation in cultured NP-C patient fibroblasts.	Vorinostat	0-10	NPC intracellular cholesterol transporter 1	Homo sapiens	116-120